The FDA has made some modest efforts, but it needs an internal organization that understands and would be an aggressive ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

If you’ve been on the internet recently, you’ve likely encountered Bryan Johnson’s meticulously optimized, data-driven quest ...

The treatment has been around for over a century but insulin has still become the centre ... Unfortunately, the current drug pricing bill fails to take a holistic approach to addressing a system ...

A popular diabetes drug just got a major new approval — and it could be a game-changer for millions of Americans at risk for kidney failure.

Purple peel exploit stands at the core of a groundbreaking revelation announced by research scientist Andrew Lambert, ...

SAN FRANCISCO, February 13, 2025 -- ( BUSINESS WIRE )-- Junevity, a biotechnology company on a mission to extend lifespan and ...

Dexcom stock stock recovered Friday after the diabetes devices maker missed fourth-quarter profit expectations.

Non-profit drugmaker Civica Rx has said it will launch biosimilars of three big-selling insulin products in the US by 2024 to help diabetic patients struggling with the cost of the drugs.

A well-known class of drugs used to manage type 2 diabetes and control weight could offer hope for patients who also struggle ...

Walgreens-Boots Alliance struggles with margin compression, competition, and financial risks. Learn why these challenges make ...

Over 66% of U.S. adults use at least one prescription drug, according to data gathered by the Health Policy Institute at ...